Ramsay Warns of Weaker Underlying Profit
Ramsay Warns of Weaker Underlying Profit
Private hospital operator Ramsay Health Care (ASX:RHC) has warned that write-downs and impairment charges against some of its European businesses will weaken its underlying 2023-24 results compared to the previous year.
私立医院运营商拉姆齐医疗保健（澳大利亚证券交易所股票代码：RHC）警告说，与去年相比，其部分欧洲业务的减记和减值费用将削弱其2023-24年的基本业绩。
However, the profit from the sale of its Sime Darby venture will significantly boost statutory profit.
但是，出售其森达比合资企业的利润将大大提高法定利润。
Ramsay expects a net profit from continuing operations of between $265 million and $270 million in the year to June. This is lower than the A$278.2 million profit reported for the 2022-23 year.
拉姆齐预计，截至6月的一年中，持续经营业务的净利润在2.65亿美元至2.7亿美元之间。这低于2022-23年报告的2.782亿澳元利润。
Statutory profit is likely to be between $884 million and $889 million, including the $618 million gain on the sale of the Ramsay Sime Darby venture.
法定利润可能在8.84亿美元至8.89亿美元之间，其中包括出售拉姆齐森达比合资企业的6.18亿美元收益。
In Monday's regulatory filing, Ramsay announced non-cash impairments and accelerated write-downs of $24.5 million against the book value of underperforming assets in both Ramsay Santé and the UK region.
在周一的监管文件中，拉姆齐宣布对拉姆齐桑特和英国地区表现不佳的资产的账面价值进行非现金减值并加速减记2450万美元。
Ramsay did, however, say it is benefiting from improving activity and labor productivity, while capital expenditure in 2023-24 was lower than forecast at around $740 million due to unexpectedly low spending in Australia.
但是，拉姆齐确实表示，它受益于活动和劳动生产率的提高，而由于澳大利亚的支出出人意料地减少，2023-24年的资本支出低于预期，约为7.4亿美元。
Ramsay is due to confirm its 2023-24 results on August 30.
拉姆齐定于8月30日确认其2023-24年的业绩。